Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab versus Keytruda in first-line metastatic NSCLC with high PD-L1 expression
2024-518629-14-00Phase 3Authorised
- Sponsor
- Summit Therapeutics
- Start
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ivonescimab with Keytruda (2 arms). Primary endpoints: Overall survival and Progression-free survival. Planned start Jun 2025; status: authorised.
02
Drugs
ivonescimabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-518629-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518629-14-00.